cilofexor

Also Known As:

2-(3-(2-Chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl)methoxy)phenyl)-3-hydroxy-1-azetidinyl)isonicotinic acid; 2-(3-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)-3-hydroxyazetidin-1-yl)isonicotinic acid

Networked: 23 relevant articles (8 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Isonicotinic Acids: 144
      - cilofexor: 23
  - Azetines
    - Azetidines: 6
      - cilofexor: 23
- Heterocyclic Acids
  - Isonicotinic Acids: 144
    - cilofexor: 23

Experts

1.	Myers, Robert P: 7 articles (06/2022 - 01/2019)
2.	Chung, Chuhan: 5 articles (06/2022 - 01/2019)
3.	Huss, Ryan S: 5 articles (06/2022 - 01/2021)
4.	Noureddin, Mazen: 5 articles (06/2022 - 01/2020)
5.	Billin, Andrew N: 4 articles (06/2022 - 01/2019)
6.	Chuang, Jen-Chieh: 4 articles (06/2022 - 01/2019)
7.	Kowdley, Kris V: 4 articles (06/2022 - 01/2019)
8.	Kohli, Anita: 4 articles (01/2022 - 01/2021)
9.	Loomba, Rohit: 4 articles (01/2022 - 01/2021)
10.	Shiffman, Mitchell L: 4 articles (07/2021 - 01/2019)

Related Diseases

1.	Fibrosis (Cirrhosis) 01/01/2019 - "In a phase II double-blind, placebo-controlled study, we tested the safety and efficacy of cilofexor (formerly GS-9674), a nonsteroidal farnesoid X receptor agonist in patients without cirrhosis with large-duct PSC. " 03/15/2023 - "The primary objective is to evaluate whether cilofexor reduces the risk of fibrosis progression compared with placebo. " 03/15/2023 - "Adults with large-duct PSC without cirrhosis are randomized 2:1 to receive oral cilofexor 100 mg once daily or placebo for up to 96 weeks during the blinded phase. " 01/09/2021 - "We studied the effects of the non-steroidal FXR agonist cilofexor (formerly GS-9674) on portal pressure and fibrosis in experimental NASH. " 11/01/2023 - "Collectively the current data show that cilofexor treatment improves cholestatic liver injury and decreases hepatic fibrosis in the Mdr2-/- mouse model of sclerosing cholangitis. "
2.	Sclerosing Cholangitis 03/15/2023 - "PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis." 01/01/2022 - "Cilofexor is a selective FXR agonist and has already entered phase III trials in primary sclerosing cholangitis (PSC) patients. " 11/01/2023 - "Here, we aimed to explore the potential of cilofexor (GS-9674), a non-steroidal FXR agonist, as a therapeutic approach for counteracting features of cholestatic liver injury by evaluating its efficacy and mechanisms in the Mdr2/Abcb4 knockout (-/-) mouse model of sclerosing cholangitis. " 11/01/2023 - "Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-/- mouse model of sclerosing cholangitis." 11/01/2023 - "Collectively the current data show that cilofexor treatment improves cholestatic liver injury and decreases hepatic fibrosis in the Mdr2-/- mouse model of sclerosing cholangitis. "
3.	Cholestasis 03/15/2023 - "Cilofexor is a nonsteroidal farnesoid X receptor agonist that demonstrated significant improvements in liver biochemistry and markers of cholestasis in patients with PSC in a phase 2 study. " 01/01/2019 - "Conclusion: In this 12-week, randomized, placebo-controlled study, cilofexor was well tolerated and led to significant improvements in liver biochemistries and markers of cholestasis in patients with PSC." 01/01/2019 - "The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis." 01/01/2023 - "In this 96-week OLE of a phase II study of PSC, cilofexor was safe and improved liver biochemistry and biomarkers of cholestasis and cellular injury. " 11/01/2023 - "Treatment with cilofexor, a non-steroidal farnesoid X receptor (FXR) agonist, improved histological features of sclerosing cholangitis, cholestasis and hepatic fibrosis in the Mdr2-/- mouse model. "
4.	Non-alcoholic Fatty Liver Disease 01/01/2020 - "We evaluated the safety and efficacy of cilofexor (formerly GS-9674), a small-molecule nonsteroidal agonist of farnesoid X receptor, in patients with nonalcoholic steatohepatitis (NASH). " 01/01/2023 - "Cilofexor is a nonsteroidal farnesoid X receptor agonist in clinical development for treatment of nonalcoholic steatohepatitis. " 01/01/2022 - "Cilofexor for the Treatment of Nonalcoholic Steatohepatitis." 12/01/2020 - "Letter to the Editor: Cilofexor in Patients With Nonalcoholic Steatohepatitis (NASH): Is It Really Effective?" 01/01/2023 - "Cilofexor is a selective farnesoid X receptor (FXR) agonist in development for the treatment of nonalcoholic steatohepatitis and primary sclerosing cholangitis. "
5.	Pruritus (Itching) 01/01/2023 - "In patients with NASH receiving cilofexor 100 mg, IL-31 was higher in those with Grade 2-3 pruritus adverse events (AEs) than those with Grade 0-1 pruritus AEs. " 01/01/2022 - "In summary, our analyses provide a molecular mechanism of cilofexor binding to FXR and provide a possible explanation for the dose-dependent pruritis of cilofexor." 01/01/2022 - "Pruritis caused by cilofexor treatment is dose dependent. " 01/01/2021 - "Pruritus occurred in 20%-29% of cilofexor versus 15% of placebo-treated patients. " 01/01/2020 - "Moderate to severe pruritus was more common in patients receiving cilofexor 100 mg (14%) than in those receiving cilofexor 30 mg (4%) and placebo (4%). "

Related Drugs and Biologics

1.	firsocostat
2.	Biomarkers (Surrogate Marker)
3.	Acetyl-CoA Carboxylase
4.	semaglutide
5.	Hydroxyproline (4 Hydroxyproline)
6.	C.I. direct red 80
7.	Drug Combinations
8.	selonsertib
9.	Thiazolidinediones
10.	saroglitazar

Related Therapies and Procedures

1.	Therapeutics